Forecyte Bio and Cytiva team up to accelerate development and manufacturing of cell and gene therapies
- Through the installation of Cytiva’s FlexFactory facilities, Forecyte Bio gains access to industry-leading GMP production platforms to manufacture viral vectors and plasmid DNA for the China and United States markets
August 25, 2022
Cytiva, a global life sciences leader, and ForecyteBio, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), are sharing expertise and advanced technology to bring better speed and efficiency to the CGT industry in China and the United States.
The two companies’ collaboration starts in Cytiva’s Fast Trak center in Shanghai, where biotech companies can quickly access industry know-how and get professional consulting and training. This will allow Forecyte Bio to launch its CDMO business quickly to win in the competitive market. With the installation of Cytiva’s FlexFactory platforms, Forecyte Bio will have good manufacturing practice (GMP) production capabilties for virus and plasmid DNA in Shanghai, China and Maryland, United States.
Lihua Yu, General Manager of Cytiva in Greater China, says: "Cytiva’s end-to-end solutions and customer-centric mindset are the foundation of this collaboration. Our vision is a world in which access to life-changing therapies transforms human health. I believe that the collaboration with Forecyte Bio will lead us one step closer to this.”
Yingke He, Founder and CEO of Forecyte Bio, says: “The collaboration will accelerate the standardization of processes in the CGT CDMO and promote the development of the industry. It will also help us offer a “one-stop” holistic service package to clients and ultimately improve patient access to cell and gene therapies.”
As biotechnology has achieved continuous breakthroughs, the expansion of the CGT industry is driving the growth of CDMOs. According to the research of Frost & Sullivan, the global CGT CDMO market is likely to reach $10.11 billion by 2026.1
Learn more about Cytiva’s Fast Trak and training services.
1 Frost & Sullivan. November 30, 2020. Technological Advancements in Manufacturing Boost the Cell and Gene Therapy Market, Says Frost & Sullivan.
About Forecyte Bio
Forecyte Bio is a CDMO company founded in 2021 to service the rapidly growing CGT industry. Built on decades of experience and expertise from its core technical experts on CGT chemistry, manufacturing, and controls (CMC) processes, Forecyte Bio offers a “one-stop” holistic service package to accelerate clients’ projects from early concept to Investigational New Drugfiling and eventual commercial manufacturing, including plasmids, viral vectors, cell products, and RNAs.
About Cytiva
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Media Contact:
Forecyte Bio
Tommy Zhang
[email protected]
Cytiva
Iris Zhao
[email protected]